[HTML][HTML] Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells

KA Jackson, SM Majka, H Wang… - The Journal of …, 2001 - Am Soc Clin Investig
KA Jackson, SM Majka, H Wang, J Pocius, CJ Hartley, MW Majesky, ML Entman, LH Michael…
The Journal of clinical investigation, 2001Am Soc Clin Investig
Myocyte loss in the ischemically injured mammalian heart often leads to irreversible deficits
in cardiac function. To identify a source of stem cells capable of restoring damaged cardiac
tissue, we transplanted highly enriched hematopoietic stem cells, the so-called side
population (SP) cells, into lethally irradiated mice subsequently rendered ischemic by
coronary artery occlusion for 60 minutes followed by reperfusion. The engrafted SP cells
(CD34–/low, c-Kit+, Sca-1+) or their progeny migrated into ischemic cardiac muscle and …
Myocyte loss in the ischemically injured mammalian heart often leads to irreversible deficits in cardiac function. To identify a source of stem cells capable of restoring damaged cardiac tissue, we transplanted highly enriched hematopoietic stem cells, the so-called side population (SP) cells, into lethally irradiated mice subsequently rendered ischemic by coronary artery occlusion for 60 minutes followed by reperfusion. The engrafted SP cells (CD34–/low, c-Kit+, Sca-1+) or their progeny migrated into ischemic cardiac muscle and blood vessels, differentiated to cardiomyocytes and endothelial cells, and contributed to the formation of functional tissue. SP cells were purified from Rosa26 transgenic mice, which express lacZ widely. Donor-derived cardiomyocytes were found primarily in the peri-infarct region at a prevalence of around 0.02% and were identified by expression of lacZ and α-actinin, and lack of expression of CD45. Donor-derived endothelial cells were identified by expression of lacZ and Flt-1, an endothelial marker shown to be absent on SP cells. Endothelial engraftment was found at a prevalence of around 3.3%, primarily in small vessels adjacent to the infarct. Our results demonstrate the cardiomyogenic potential of hematopoietic stem cells and suggest a therapeutic strategy that eventually could benefit patients with myocardial infarction.
The Journal of Clinical Investigation